Al Sandrock, Voyager CEO

Voy­ager nabs $25M cash as No­var­tis runs with two AAV cap­sids for neu­ro gene ther­a­py

Af­ter spend­ing a year look­ing at Voy­ager’s next-gen AAV cap­sids, No­var­tis has picked two of them to be the de­liv­ery vec­tor for its gene ther­a­py pro­grams tar­get­ing two neu­ro­log­ic dis­eases.

The li­cense trig­gers a $25 mil­lion pay­ment — $12.5 mil­lion for each tar­get — and opens up a road to $600 mil­lion in to­tal mile­stones. But it al­so leaves some mon­ey off the ta­ble as No­var­tis, which had the op­tion to li­cense cap­sids against a to­tal of three tar­gets, de­cid­ed not to act on the third.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.